Proteomic and Genomic Profiling of Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 5767
Special Issue Editor
Interests: pancreatic cancer; Immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic cancer is one of the deadliest forms of cancer, with a 5-year survival rate of 10%. The most common treatment for pancreatic cancer is surgery and chemotherapy; however, to date, both strategies have had limited success. To combat pancreatic cancer, in recent years, a significant amount of attention has been paid to immunotherapy and personalized medicine. PD1 therapy and presently available CART therapies are failing to treat pancreatic cancer, and there is a pressing need to collect more clinical biomarkers for the development of new therapeutic targets for personalized medicine. In the age of high-throughput techniques, genomics and proteomics in particular have had a significant impact on identifying mutations in oncogenes such as KRAS and other relevant new biomarkers for chemotherapy and immunotherapy. In addition, proteomic profiling of pancreatic cancer targeting secretomes will provide further insight into the tumor microenvironment, leading to a pivotal understanding of pancreatic cancer progression and immune response. Using the current understanding of immunotherapy, genomics and proteomics analysis of pancreatic cancer patient samples will lead to the discovery of new targets that will help in the development of novel therapeutics.
Dr. Aftab Alam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- CART
- chemotherapy
- immunotherapy
- PD1
- biomarker
- personalized medicine
- secretome
- genomics
- proteomics
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
